Review Highlights Multiple Treatment Options Available in DLBCL

Why It Matters

These novel immunotherapies markedly improve outcomes for relapsed/refractory DLBCL, but their complexity underscores the need for precision strategies and broader accessibility.

Key Takeaways

• R-CHOP cures ~60%; 30-40% relapse.
• CAR T therapies show 80%+ response rates in trials.
• Polatuzumab plus R-CHP improves 2‑year PFS to 77%.
• Bispecific antibodies provide off‑the‑shelf options with 60%+ ORR.
• Molecular heterogeneity demands biomarker‑driven treatment sequencing.

Pulse Analysis

Diffuse large B‑cell lymphoma remains a therapeutic challenge because its biological diversity translates into variable responses to standard chemoimmunotherapy. The frontline R‑CHOP regimen, despite being the backbone for decades, leaves a sizable fraction of patients with disease that either returns or never responds. This unmet need has accelerated research into targeted immunotherapies, prompting a wave of approvals that now span cellular, conjugate, and bispecific modalities. Understanding the landscape requires not only familiarity with trial outcomes but also insight into how disease subtyping—GCB versus ABC and emerging genetic clusters—guides therapeutic choice.

CAR‑T cell therapy has evolved from a niche, heavily regulated option to a mainstream second‑line treatment, as demonstrated by axi‑cel’s 82% overall response and liso‑cel’s 87% response in pivotal phase 3 studies. Yet durability varies; antigen loss, T‑cell exhaustion, and an immunosuppressive microenvironment limit long‑term remission for many. Next‑generation constructs aim to enhance persistence and reduce cytokine release syndrome, while combination strategies with checkpoint inhibitors or targeted agents are under active investigation. Parallel advances in antibody‑drug conjugates, such as polatuzumab‑vedotin improving two‑year progression‑free survival to 77%, provide chemo‑free alternatives that retain efficacy even after CAR‑T failure.

Bispecific antibodies, including epcoritamab and glofitamab, further diversify the armamentarium by offering off‑the‑shelf, T‑cell‑engaging therapies with response rates exceeding 60% in heavily pretreated cohorts. Their subcutaneous formulations and fixed‑duration regimens improve patient convenience and may lower health‑system costs. However, optimal sequencing—whether to deploy a bispecific before or after CAR‑T, or to combine ADCs with novel checkpoint blockers—remains an open question. The review emphasizes that integrating multi‑omics profiling and real‑world safety data will be critical to tailor these powerful tools, maximize benefit, and ultimately shift DLBCL from a largely fatal disease to a manageable chronic condition.